Login / Signup

Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease.

Mafalda C RamosVolker FoosAnastasia UstyugovaNikco HauPranav GandhiMark Lamotte
Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2019)
Boehringer Ingelheim International GmbH.
Keyphrases
  • cardiovascular disease
  • cardiovascular risk factors
  • metabolic syndrome
  • coronary artery disease
  • clinical evaluation